JR9000

N/A

Report date: 2023/03/03 14:36:47
NME

Base Information

Drug NameJR9000
Drug Alias NameJR9000JR-9000
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionKRAS G12D inhibitors
TargetsKRAS G12D
Therapy Area/IndicationsLung NeoplasmsPancreatic NeoplasmsColonic Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesJingrui Pharmaceutical (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJingrui Pharmaceutical (Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsPancreatic NeoplasmsColonic Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A